Related references
Note: Only part of the references are listed.Cardiovascular Events in Patients With Fabry Disease Natural History Data From the Fabry Registry
Manesh R. Patel et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2011)
Expert opinion on temporary treatment recommendations for Fabry the disease during the shortage of enzyme replacement therapy (ERT)
Gabor E. Linthorst et al.
MOLECULAR GENETICS AND METABOLISM (2011)
Screening for Fabry disease in high-risk populations: a systematic review
G. E. Linthorst et al.
JOURNAL OF MEDICAL GENETICS (2010)
Long-Term Effects of Enzyme Replacement Therapy on Fabry Cardiomyopathy Evidence for a Better Outcome With Early Treatment
Frank Weidemann et al.
CIRCULATION (2009)
A 4-year study of the efficacy and tolerability of enzyme replacement therapy with agalsidase alfa in 36 women with Fabry disease
Catharina Whybra et al.
GENETICS IN MEDICINE (2009)
Natural course of Fabry disease: changing pattern of causes of death in FOS - Fabry Outcome Survey
A. Mehta et al.
JOURNAL OF MEDICAL GENETICS (2009)
Agalsidase Alfa and Kidney Dysfunction in Fabry Disease
Michael West et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2009)
Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data
A. Mehta et al.
LANCET (2009)
Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy
Raphael Schiffmann et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2009)
Stroke in Fabry Disease Frequently Occurs Before Diagnosis and in the Absence of Other Clinical Events Natural History Data From the Fabry Registry
Katherine Sims et al.
STROKE (2009)
Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa
D. A. Hughes et al.
HEART (2008)
Terminal stage cardiac findings in patients with cardiac Fabry disease: An electrocardiographic, echocardiographic, and autopsy study
Toshhihiro Takenaka et al.
JOURNAL OF CARDIOLOGY (2008)
Central nervous system involvement in Anderson Fabry disease: a clinical and MRI retrospective study
S. Buechner et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2008)
Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy
Alberto Ortiz et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2008)
Sustained, long-term renal stabilization after 54 months of agalsidase β therapy in patients with Fabry disease
Dominique P. Germain et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2007)
Agalsidase-beta therapy for advanced Fabry disease - A randomized trial
Maryam Banikazemi et al.
ANNALS OF INTERNAL MEDICINE (2007)
Fabry disease model: A rational approach to the management of Fabry disease
Christoph Wanner
CLINICAL THERAPEUTICS (2007)
Fabry disease: The need to stratify patient populations to better understand the outcome of enzyme replacement therapy
Dominique P. Germain
CLINICAL THERAPEUTICS (2007)
Impact of enzyme replacement therapy on cardiac morphology and function and late enhancement in Fabry's cardiomyopathy
Meinrad Beer et al.
AMERICAN JOURNAL OF CARDIOLOGY (2006)
Clinical benefit of enzyme replacement therapy in Fabry disease
F Breunig et al.
KIDNEY INTERNATIONAL (2006)
Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting
R Schiffmann et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2006)
Fabry disease: Guidelines for the evaluation and management of multi-organ system involvement
Christine M. Eng et al.
GENETICS IN MEDICINE (2006)
Prevalence of Fabry disease in patients with cryptogenic stroke:: a prospective study
A Rolfs et al.
LANCET (2005)
The variation of morphological and functional cardiac manifestation in Fabry disease:: potential implications for the time course of the disease
F Weidemann et al.
EUROPEAN HEART JOURNAL (2005)
Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey
A Mehta et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2004)
Long-term safety and efficacy of enzyme replacement therapy for Fabry disease
WR Wilcox et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2004)
Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease - A prospective strain rate imaging study
F Weidemann et al.
CIRCULATION (2003)
Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease - Evidence for a disease specific abnormality of the myocardial interstitium
JCC Moon et al.
EUROPEAN HEART JOURNAL (2003)
Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart - A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association
MD Cerqueira et al.
CIRCULATION (2002)
Safety and efficacy of recombinant human α-galactosidase a replacement therapy in Fabry's disease.
CM Eng et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Enzyme replacement therapy in Fabry disease - A randomized controlled trial
R Schiffmann et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2001)
Natural history of Fabry disease in affected males and obligate carrier females
KD MacDermot et al.
JOURNAL OF INHERITED METABOLIC DISEASE (2001)
Share Paper
